目的 探討泮托拉唑鈉腸溶膠囊聯(lián)合吉法酯片對(duì)經(jīng)皮冠狀動(dòng)脈介入治療（PCI）術(shù)后雙聯(lián)抗血小板藥物治療的患者上消化道出血的預(yù)防作用。方法 選取2014年10月-2017年10月在西電集團(tuán)醫(yī)院行PCI的患者121例作為研究對(duì)象，按照入院先后順序分為兩組。對(duì)照組在術(shù)后第1天開(kāi)始口服吉法酯片，100 mg/次，3次/d。觀察組在對(duì)照組的基礎(chǔ)上聯(lián)合泮托拉唑鈉腸溶膠囊，40 mg/d。比較兩組患者術(shù)后6個(gè)月內(nèi)上消化道出血的發(fā)生率、心血管不良事件、消化道不良反應(yīng)和血小板聚集率。結(jié)果 術(shù)后6個(gè)月觀察組患者的上消化道出血發(fā)生率顯著低于對(duì)照組（P<0.05）；心血管不良事件發(fā)生率兩組比較無(wú)統(tǒng)計(jì)學(xué)差異，觀察組消化道不良反應(yīng)發(fā)生率顯著低于對(duì)照組（P<0.05）。兩組患者治療前后的血小板聚集率相比無(wú)統(tǒng)計(jì)學(xué)差異。結(jié)論 泮托拉唑鈉腸溶膠囊聯(lián)合吉法酯片對(duì)PCI術(shù)后雙聯(lián)抗血小板藥物治療患者上消化道出血具有較好的預(yù)防作用，且顯著降低消化道不良反應(yīng)發(fā)生率，不增加心血管不良事件發(fā)生率，值得臨床應(yīng)用。

Objective To explore the preventive effect of Pantoprazole Sodium Enteric-coated Capsules combined with Gefarnate Tablets on upper gastrointestinal hemorrhage after dual antiplatelet treatment of PCI patients. Methods Patients (121 cases) who received percutaneous coronary intervention (PCI) in Xi'an XD Group Hospital from October 2014 to October 2017 were selected and divided into two groups according to the sequence of admission. Patients in the control group began to take Gefarnate Tablets orally on the first day after the operation, 100 mg/time, three times daily. Patients in the observation group were po administered with Pantoprazole Sodium Enteric-coated Capsules on the basis of control group, 40 mg/d.The incidence of upper gastrointestinal hemorrhage, cardiovascular adverse events, gastrointestinal adverse reactions and platelet aggregation within 6 months after surgery were compared between two groups. Results Within 6 months after surgery, the incidence of upper gastrointestinal hemorrhage in the observation group was significantly lower than that in the control group (P<0.05). There was no statistical difference in the incidence of cardiovascular adverse events between the two groups, and the incidence of gastrointestinal adverse reactions in the observation group was significantly lower than that in the control group (P<0.05). There was no significant difference in platelet aggregation before and after treatment between the two groups. Conclusion Pantoprazole Sodium Enteric-coated Capsules combined with Gefarnate Tablets has a good preventive effect on upper gastrointestinal hemorrhage after dual antiplatelet treatment of PCI patients, and significantly reduces the incidence of gastrointestinal adverse reactions and does not increase the incidence of cardiovascular adverse events, which is worthy of clinical reference.